...
首页> 外文期刊>Cell death & disease. >FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness
【24h】

FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness

机译:FOXM1通过调节UHRF1控制的癌细胞干性而促进紫杉烷抗性

获取原文
           

摘要

Therapy-induced expansion of cancer stem cells (CSCs) has been identified as one of the most critical factors contributing to therapeutic resistance, but the mechanisms of this adaptation are not fully understood. UHRF1 is a key epigenetic regulator responsible for therapeutic resistance, and controls the self-renewal of stem cells. In the present study, taxane-resistant cancer cells were established and stem-like cancer cells were expanded. UHRF1 was overexpressed in the taxane-resistant cancer cells, which maintained CSC characteristics. UHRF1 depletion overcame taxane resistance in vitro and in vivo. Additionally, FOXM1 has been reported to play a role in therapeutic resistance and the self-renewal of CSCs. FOXM1 and UHRF1 are highly correlated in prostate cancer tissues and cells, FOXM1 regulates CSCs by regulating uhrf1 gene transcription in an E2F-independent manner, and FOXM1 protein directly binds to the FKH motifs at the uhrf1 gene promoter. This present study clarified a novel mechanism by which FOXM1 controls CSCs and taxane resistance through a UHRF1-mediated signaling pathway, and validated FOXM1 and UHRF1 as two potential therapeutic targets to overcome taxane resistance.
机译:治疗诱导的癌症干细胞(CSC)扩增已被确定为导致治疗耐药性的最关键因素之一,但这种适应的机制尚未完全明了。 UHRF1是负责治疗抗性的关键表观遗传调控因子,它控制干细胞的自我更新。在本研究中,建立了抗紫杉烷类癌细胞并扩增了干细胞样癌细胞。 UHRF1在耐紫杉烷的癌细胞中过表达,并保持CSC特性。 UHRF1耗竭在体外和体内克服了紫杉烷抗性。另外,据报道FOXM1在治疗抗性和CSC的自我更新中起作用。 FOXM1和UHRF1在前列腺癌组织和细胞中高度相关,FOXM1通过以E2F无关的方式调节uhrf1基因转录来调节CSC,FOXM1蛋白直接与uhrf1基因启动子上的FKH基序结合。本研究阐明了FOXM1通过UHRF1介导的信号通路控制CSC和紫杉烷抗性的新机制,并验证了FOXM1和UHRF1作为克服紫杉烷抗性的两个潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号